No Data
No Data
Kyverna Therapeutics | 10-Q: Quarterly report
Kyverna Therapeutics Q1 2024 Adj EPS $(1.12) Misses $(0.84) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0.84) by 33.33 percent.
Press Release: Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results PR Newswire EMERYVILLE, Calif., May 14, 2024 -- Advanced clinical development in two broad areas of
8 Out of 12 S&P 500 Healthcare Companies Beat Profit Consensus This Week: Earnings Scorecard
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it
Buy Rating Affirmed for Kyverna Therapeutics on Promising KYV-101 Drug Efficacy and Safety Data
In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Kyverna Therapeutics, Inc. (KYTX – Research Report), with a price target of $44.00.
No Data